Collaboration Connects Early Autism Diagnosis with High-Quality, Outcomes-Driven Care Amid Industry-Wide Access Issues Press release | April 21, 2026 In a strategic move that unites one of the nation’s largest behavioral health networks with FDA-authorized diagnostic technology, the nonprofit Catalight Group and Cognoa have partnered to scale a streamlined journey from early autism diagnostic evaluation to evidenced-based treatment that fits families’ needs. As autism prevalence has climbed to 1 in 31 children in the United States, the demand for diagnostic evaluation and service is far outweighing the supply of qualified professionals who are able to provide them. Workforce shortages leave families facing developmental concerns for their children waiting months or even years for an autism evaluation during critical periods of neurodevelopment. Research has shown that such delays directly undermine long-term outcomes. With the partnership, Cognoa, the maker of Canvas Dx™ – the first and only FDA-authorized diagnostic AI solution designed to help clinicians diagnose or rule out autism in children as young as 18 months – expands the ability to serve post-diagnosis with The Catalight Group’s vast network of more than 15,000 practitioners delivering personalized services to upwards of 25,000 patients annually. Using AI trained on diverse datasets across race, gender, geography and socioeconomic background, primary care physicians can use Canvas Dx to diagnose patients in days and refer them to The Catalight Group for immediate care. “For too long, the path from a family’s first concern to a confirmed diagnosis and then from diagnosis to the right care has been broken into disconnected pieces, with families left to navigate each gap on their own,” said Cognoa CEO Sharief Taraman. “This partnership with Catalight changes that equation. By connecting Canvas Dx’s diagnostic capability directly to Catalight’s world-class care network, we’re creating something the field has needed for years: A genuine end-to-end pathway that starts early, moves fast and is effective for children and their families.” In a time when it can take 12-24 months for a diagnosis alone, Catalight can place patients into care within 10 business days of the assessment. The powerful combination of cutting-edge technology with an unparalleled care network allows the organizations to offer greater access and the ability to serve more families without increasing wait times. “We’ve always believed that every person deserves timely access to care, no matter where they live, who they are or what their diagnosis looks like. Belief alone, however, is not enough. Families need a system that actually works for them – one that starts with a timely and clinically supported diagnosis, connects them to precise care and measures what matters,” said Susan Armiger, CEO of The Catalight Group. “That is exactly why this partnership with Cognoa is so important to us. Together, we are showing that equitable, sustainable autism care that focuses on quality of care over quantity of hours is possible. That should be the standard, not the exception.” The collaboration is grounded in a shared, evidence-backed commitment to value-based, precision care that measures outcomes in greater wellbeing and a higher quality of life. The Catalight Group, operating under value-based agreements, has achieved cost reductions of 30%. Its research consistently shows that lower-hour, individualized care produces outcomes equal to or better than traditional high-hour models. Cognoa’s Canvas Dx has demonstrated that earlier, accurate diagnosis reduces downstream costs for payers and is already covered as a benefit under select commercial, private payer and Medicaid programs. This partnership creates a continuous, transparent journey for each child – enabling payers, providers and families to track real outcomes from the moment of concern through active treatment and beyond. “States and payers are asking hard questions about accountability in autism care. We believe this model — objective diagnosis, individualized treatment, outcomes-based payment — is exactly the answer,” Taraman said. The combined reach of this partnership positions both organizations to extend equitable, connected care to communities where the system has historically failed. Contact: Keith FergusonCatalightDirector of Marketing and Communications925-532-9615 Emily DeLongCognoa650-206-9273
press release | April 7, 2026 Study Reveals Shift in How Families Define Success in Autism Treatment Read press release
in the news | April 6, 2026 Modern Autism Care Requires a New Approach to Education: Catalight Academy’s Model for Clinician Training Read News
press release | March 6, 2026 Catalight Academy Grows Leading Nonprofit’s Autism and I/DD Clinical Training Capability Read press release
press release | February 24, 2026 Study Links Poor Sleep to Increased Risky Behavior Among Autistic People Read press release
press release | February 10, 2026 New Online Screener Offers Path to Autism Diagnosis and Care Read press release
in the news | January 20, 2026 More Treatment Hours May Not Yield Autistic Children’s Skills Improvement: Study Read News
press release | January 19, 2026 Leading Nonprofit Catalight Brings Value-Based Autism Care to the Global Stage at the World Economic Forum in Davos Read press release
press release | January 12, 2026 Catalight and Frontera Partner to Reduce Cost and Improve Quality of Autism Care Read press release
article | October 23, 2025 Catalight’s Postdoctoral Program Inaugural Year: Success, Learnings and Trainee Experience Read article